Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals director William J. Link, PhD reported selling 12,500 shares of common stock in open-market transactions. On June 15, 2026, he executed two sales of 10,572 and 1,928 shares at weighted average prices of $61.97 and $62.94 per share.
The filing states these were automatic sales under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025, meaning the trades were scheduled in advance rather than timed discretionarily. Prices for each block were achieved across multiple trades within disclosed price ranges.
TARS filed a Form 144 reporting a scheduled restricted stock vesting and recent insider transactions. The filing lists 14,396 shares of Common stock tied to a 06/15/2026 restricted stock vesting classified as Compensation. It also discloses sales by Jeffrey Farrow on 03/17/2026 (2,111), 03/18/2026 (2,133) and 03/19/2026 (2,186), with dollar figures shown alongside each trade.
Tarsus Pharmaceuticals director Scott W. Morrison reported a routine equity compensation event. On June 12, 2026, 2,954 Restricted Stock Units (RSUs) vested and were settled into 2,954 shares of common stock at a per-share price of $0.00, reflecting a derivative exercise.
Following this settlement, Morrison directly held 7,638 shares of Tarsus common stock. He also indirectly held 6,016 shares through the Morrison-Minton Family 2004 Trust, where he serves as trustee and he and his spouse are the sole beneficiaries. No open-market purchases or sales were reported in this filing.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals, Inc. director William J. Link, PhD received 2,954 shares of common stock through the settlement of an equal number of vested Restricted Stock Units. These RSUs were granted on June 12, 2025 for his service as a non-employee director and vested after one year. Following this automatic equity settlement, he directly holds 119,286 common shares, with no shares sold or withheld for taxes in this Form 4.
Tarsus Pharmaceuticals director Bhaskar Chaudhuri acquired 2,954 shares of Common Stock through the settlement of vested Restricted Stock Units (RSUs). These RSUs each converted into one share of common stock, a standard equity compensation event rather than an open-market trade.
Following this transaction, Chaudhuri directly holds 11,654 shares of Tarsus common stock. The derivative RSU position underlying these 2,954 shares was fully settled, with no remaining RSUs from this specific grant shown in the filing.
Tarsus Pharmaceuticals director Katherine Goodrich acquired common shares through an equity award vesting, not an open-market purchase. On June 12, 2026, 2,954 Restricted Stock Units (RSUs) settled into 2,954 shares of Tarsus common stock at a price of $0.00 per share, reflecting a compensation-related equity grant.
Following this RSU settlement, Goodrich directly owns 5,187 shares of Tarsus common stock. No shares were reported as sold or disposed of in this filing, and no tax-withholding or gifting transactions were disclosed.
Tarsus Pharmaceuticals director Wendy L. Yarno acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs). Each RSU converted into one share of common stock, reflecting compensation for her service as a non-employee director. The RSUs were granted on June 12, 2025 and vested in full on the one-year anniversary of the grant date, subject to continuous service. Following this RSU settlement, Yarno directly holds 16,654 shares of Tarsus Pharmaceuticals common stock, and the RSU balance from this grant is now fully settled.
Tarsus Pharmaceuticals director Andrew D. Goldberg acquired 2,954 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs). The RSUs were granted on June 12, 2025 for his service as a non-employee director and vested in full one year later.
Following this compensation-related share issuance, Goldberg directly holds 19,654 shares of Tarsus common stock. The filing shows no open-market purchases or sales, only the conversion of previously granted RSUs into common shares.
Tarsus Pharmaceuticals, Inc. filed a Form 144 notifying a proposed sale of 12,500 shares of Common Stock by William J. Link. The shares are identified as from a Stock Option Exercise dated 01/10/2017 and the method of sale is listed as Cash.
The filing also lists a sale of 12,500 shares on 03/16/2026 with proceeds of $859,787.14.